LANTERN PHARMA INCORPORATED (LTRN)

Investors are closely monitoring the situation to assess future performance and potential recovery in the stock’s valuation. In other recent news, L3Harris Technologies announced its second-quarter 2026 financial results, surpassing market expectations. The company reported adjusted earnings of ...

DALLAS - Lantern Pharma Inc. (NASDAQ:LTRN) announced that the European Medicines Agency has cleared an investigator-initiated Phase 1b/2 clinical trial of LP-184 in advanced bladder cancer, according to a press release statement.

A completed 63-patient Phase 1a trial showed a 45% disease control rate at or above the effective dose; Phase 1b/2 trials are planned for 2026.

The Tickeron PE Growth Rating for ... average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents. The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), …

Technicals provide some near-term ... constrained by negative earnings and no dividend, while recent financing and the proposed AI spinoff modestly improve the outlook but do not offset core cash-burn risk. To see Spark’s full report on LTRN stock, click here....